Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexari ...

Novo Nordisk has initiated a legal confrontation against telehealth platform Hims & Hers following its announcement of a ...

The new leadership mandate is clear: Inspire first. Require next. The companies that master this balance and cultivate a ...

Thank you, and welcome to everybody joining us today. Alongside this, we're continuing to make excellent progress in R&D, strengthening our late-stage portfolio and already securing four FDA approvals ...

AI now mediates how customers discover and choose local services. Learn how AI systems evaluate trust, data quality, and ...

Revenue increased 19% to $65.6 billion GAAP1 operating earnings increased 29% to $707 million; GAAP diluted EPS increased 19% to $1.97 Non-GAAP operating earnings ...